Analyzing 250 biomarkers in a single test, Molecular You aims to bring ‘scientific discipline and clinical-grade rigor’ to consumer wellness.
Preventive health startup Molecular You has raised $5 million in Series A financing to scale its predictive health platform. Based in Portland, Oregon, and Vancouver, British Columbia, the company plans to use the funding to grow its customer base in North America while continuing to expand the analytical scope of its technology.
Designed to identify disease risks before symptoms appear, Molecular You relies on a single blood draw to measure more than 250 biomarkers spanning all major biological systems. By analyzing these results across 25 health areas, the platform produces a comprehensive snapshot of an individual’s current and potential health risks. Results are paired with personalized recommendations for diet, lifestyle, and supplements, supported by evidence-based research and updated as new findings emerge.
The company’s business model is designed to serve both individuals directly and physicians in clinical practice. For individuals, the Molecular You test is priced at a cool $1,100. With companies like Function Health, Hundred Health and Superpower offering blood-test based offerings for less than half that amount (Superpower this week announced a $199 test spanning more than a hundred biomarkers), it will be interesting to see how Molecular You’s consumer pricing evolves in this increasingly competitive market segment.
It appears that one way Molecular You differentiates itself is on depth and breadth of its analysis. The company is preparing to introduce its next-generation assay, which will expand measurement to more than 800 biomarkers, while also broadening its clinical applications, including detection of certain cancers. Reports provide actionable information designed to help guide preventive steps, track changes over time and intervene earlier in disease progression. The company says its holistic measurement of interrelated biomarkers enables predictive power for complex conditions such as autoimmune disorders, polycystic ovary syndrome and neurodegenerative diseases.
Founded in Vancouver in 2014, Molecular You was a spin-off of the Personalized Medicine Initiative, a project led by Canadian scientists and clinicians including co-founder Rob Fraser. The initiative sought to advance individualized approaches to care, and the company was created to translate that vision into commercial practice. Leadership at the company includes CEO Jim Kean, who previously founded the digital health company WellnessFX and helped build the consumer-facing platform at WebMD, and chief medical officer Dr Murdoc Khaleghi.
“We’re bringing scientific discipline and clinical-grade rigor to the booming consumer wellness sector and delivering brand new tools to enhance what clinical practices can provide,” said Khaleghi. “Fragmented measurement of individual biomarkers cannot offer the same predictive capabilities as our platform, which sees the body as a whole. This is critical for predictive and preventative medicine, particularly for complex conditions like Alzheimer’s, PCOS, and autoimmune diseases, which are correlated to multiple individual biomarkers that are typically measured separately.”
The round was led by data science firm Voloridge Health, in what appears to be a strategic investment, with participation from Dynamic Leap and other backers.
“Molecular You is advancing a critical shift in healthcare, from reactive treatment to predictive and preventive care, through biomarker science and real-world clinical impact,” said Voloridge CEO David Vogel. “Their unique multi-omic platform integrates proteomics and metabolomics in a way that sets a new standard for precision health.”
